UNSPSC 51384204: Piketoprofen

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 362QBC4NL0. European Medicines Agency schedules Piketoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09832MIG. Piketoprofen generally arises in the molecular formula C22H20N2O2.

UNSPSC 51384204 Piketoprofen is a Commodity code for a specific nonsteroidal anti-inflammatory drug, yet the recent state and local solicitations tagged under it do not procure piketoprofen itself. Instead, they reflect a broader state and local procurement pattern around pharmaceutical products, drug-management systems, and pharmacy benefit administration. The code shows limited direct relevance to typical piketoprofen purchasing; the recent opportunities instead cover naloxone and safe drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing. This mismatch suggests that either the code is being used as a catch-all pharmaceutical category by some issuing bodies or that the recent opportunities represent adjacent pharmaceutical-procurement activity rather than piketoprofen-specific demand.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). Recent opportunities span Florida, Texas, and Minnesota, with the Minnesota cooperative reaching across multiple states including Oregon. Representative recent work includes Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response date of July 26, 2023; Texas HHS Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription programs with an April 3, 2026 response deadline; and MMCAP's S1070000015802 RFP for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with proposals due March 26, 2026. The code does not show established baseline demand for piketoprofen specifically under recent state and local purchasing activity.